Ranbaxy gains on Prilosec generic

Ranbaxy Laboratories got a welcome dose of good news as its shares climbed more than 3 percent on the launch of its generic version of the acid reflux drug Prilosec in the U.S., under an agreement with AstraZeneca. Report